The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder
Marlise R. Luskin(Harvard University), Ran Reshef(Abramson Cancer Center), Daniel F. Heitjan(Abramson Cancer Center), Edward A. Stadtmauer(University of Pennsylvania), Robert H. Vonderheide(Parker Institute for Cancer Immunotherapy), David L. Porter(University of Pennsylvania), Kay See Tan(University of Pennsylvania), Stephen J. Schuster(UPMC Hillman Cancer Center), Daniel S. Heil(University of Pennsylvania), Adam Bagg(University of Pennsylvania), Soo Jin Choi(University of Pennsylvania), Donald E. Tsai(University of Pennsylvania)
Cited by 174
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
|Cancer Immunology Research|2015|467